Renal Cell Carcinoma Clinical Roundup

News Articles

(RSNA) June 9, 2020 - Freezing cancer cells in early-stage kidney cancer offers similar results as surgery with lower risks of complications.
(Dana-Farber) May 29, 2020 - By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.
(Yahoo! Finance) May 29, 2020 - AVEO Oncology today announced the presentation of results from the final analysis of overall survival (OS) in its pivotal Phase 3 TIVO-3 trial comparing tivozanib, the Company’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI), to sorafenib in 3rd and 4th...
(MD Anderson) May 28, 2020 - In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of hypoxia-inducible factor (HIF)-2a was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease (VHL)–associated...
View all renal cell carcinomca (rcc) cancer news

Podcasts

podcastImage
Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Tian Zhang, MD, Assistant Professor of Medicine, Duke University School of Medicine, discuss the progress in RCC presented at ASCO GU '20

Featured Kidney (Renal Cell Carcinoma) Cancer Tweets

Tian Zhang, MD, MHS
TiansterZhang - Jun 17  Great Venn diagram for biomarkers of IO therapies from @VivekSubbiah. 4th circle important - research on the TILs a… https://t.co/ifMlGf2d7O

Toni Choueri, MD
DrChoueiri - Jun 16  Important trial and has the potential to be the first biomarker based adjuvant option in GU cancers @OncoAlert https://t.co/B5q65xugmy

Rana McKay, MD
DrRanaMcKay - Jun 12  Intense neoadjuvant ADT results in pathologic responses in high risk patients. Combination under investigation in p… https://t.co/1E574256h3